Neurocrine Biosciences, Inc. Aktie News

Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and concludes t...

Nvidia earnings have cast a light on defensive areas, inducing a sector rotation that may accelerate in the short term. Looking beyond NVDA earnings, an economic environment characterized by slowing growth, persistent inflation, and tariff uncertainty is compelling investors to look beyond overbought tech. This shift favors sectors that offer resilience, stable cash flow, and intrinsic value ov...

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with increased marketing, while Crenessity's rapid uptake suggests over $1B in peak revenue potential. The late-stage pipeline, including direclidine and osavampator, offers high-risk/high-reward oppor...

Neurocrine Biosciences, Inc. ( NBIX ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Kyle Gano - CEO & Director Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Phoebe Tan - Jefferies LLC, Research Division Presentation Phoebe Tan Jefferies LLC, Research Division Hi, everyone. My name is ...

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London Piper Sandler 37th Annual Healthcare Conference.

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated.

The volatile sector is seeing greater stability, and these four stocks can profit.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, In...